Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhGM-CSF gel is a topical pharmaceutical formulation containing recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). It is primarily used to promote wound healing, particularly for deep second-degree burns and chronic skin ulcers such as pressure ulcers, venous ulcers, and diabetic foot ulcers. The active ingredient, rhGM-CSF, functions as a cytokine that stimulates the production, proliferation, and differentiation of granulocytes and macrophages. By modulating the biological properties of these immune cells during the inflammation phase, it accelerates wound repair, facilitates angiogenesis (formation of new blood vessels), promotes re-epithelialization, and enhances the growth of granulation tissue, contributing to infection control and overall wound closure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhGM-CSF gel.